1. Big Pharma are sitting with huge cash hoards on their balance sheets earning a paltry after-tax interest.
[etc.]
<<
But in 2009 there will likely be a large number of extremely cash-desperate biotechs with horribly depressed stock prices and difficulty accessing the credit markets.
If they can avoid bidding wars, Big Pharma can pick these off for pennies on the dollar.